66th ASH Annual Meeting: 701. Experimental Transplantation: Basic and Translational: Poster III

Symposia: Experimental Transplantation: Basic and Translational Oral and Poster Abstracts
Poster

Research, Antibody Therapy, Acquired Marrow Failure Syndromes, Sickle Cell Disease, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, AML, MDS, Fundamental Science, Clinical trials, Apoptosis, Adult, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Lymphomas, CLL, Drug development, MPN, Translational Research, Plasma Cell Disorders, LGL, CML, Clinical Research, Hemoglobinopathies, GVHD, Chronic Myeloid Malignancies, CMML, Diseases, Immune Disorders, Immune mechanism, Gene Therapy, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Adverse Events, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Microbiome, Monoclonal Antibody Therapy, Technology and Procedures, Gene editing, Molecular biology, Study Population, Human, Transplantation (Allogeneic and Autologous)

Halls G-H (San Diego Convention Center)

4767

Epitope Editing Combined with Extended Schedule Anti-KIT Antibody Treatment Allows Immune-Based In Vivo Selection of Multiplex Genome-Engineered Cells

Gabriele Casirati, MD, PhD¹, Adele Mucci, PhD²^*, Marta Freschi, MSc³^*, Andrea Cosentino, MD³^*, Mohammed S Mahmoud, PhD⁴^*, Jing Zeng, MD², Nola Neri²^*, Christian Brendel, PhD²^*, Daniel Bauer⁵ and Pietro Genovese, PhD⁶

¹Hematology Oncology, Boston Children's Hospital/Dana Farber Cancer Institute, Boston, MA
²Hematology/Oncology, Boston Children's Hospital, Boston, MA
³Boston Children Hospital, Boston, MA
⁴Fayoum University, Department of Zoology, College of Science, Fayoum, Egypt
⁵Harvard University, Boston, MA
⁶Boston Children's Hospital, Boston, MA

4768

Human Lung Organoid Model of Bronchiolitis Obliterans Syndrome Following Hematopoietic Cell Transplantation

Jihoon Lee¹^*, Amitej Venapally, BS²^*, Ruri Maekawa, BS²^*, Shuichi Takayama, PhD²^* and Kirsten M. Williams, MD³

¹David Geffen School of Medicine, Los Angeles, CA
²Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA
³Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA

4769

Ezh2 and Intracellular Ca2⁺ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Ying WANG¹^*, Qingrong Huang²^*, Ruqayyah sanders-Braggs³^*, Yan Zhou, MS⁴^*, Robert Hooper⁵^*, Yuanyuan Tian, PhD⁶^*, Tatiana Kent, PhD⁷^*, Richard Pomerantz, PhD⁷^*, Gennaro Clando⁸^*, Jean-Pierre Issa⁸^*, Jonathan Soboloff⁹^* and Yi Zhang, MD, PhD⁶

¹Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ
²Clinical Immunology Core, Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
³Center for Discovery and Innovation, Hackensack University Medical Center, Nutley
⁴Fox Chase Cancer Center, Temple University, Philadelphia
⁵Temple University, Philadelphia, PA
⁶Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
⁷Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
⁸Coriell Institute for Medical Research, Camden, NJ
⁹Temple University School of Medicine, Philadelphia, PA

4770

Single Dose of Tgroβ (EN-145)/Plerixafor Safely and Effectively Mobilizes Primitive HSCs in Mouse Models for In Vivo Gene Therapy of Sickle Cell Disease

Courtney Mercadante, PhD¹^*, Vemika Chandra, PhD¹^*, Miriama Kruta Vincent²^*, Herika Fernandez²^*, Jinpeng Wang³^*, Brian Zifcak³^*, Kayla Frank¹^*, Robert T. Peters, PhD¹, Joe Salas, PhD¹ and Pauline Rimmele, PhD¹

¹Ensoma, Inc., Boston, MA
²Ensoma, Boston, MA
³Ensoma, Inc., Boston

4771

Identification of Microbiota-Reactive CD4+ T Cells in the Post-Transplant Setting

Albert C Yeh, MD¹, Tanya Cunningham²^*, Saranya R. Chakka³^*, R Graeme Black³^*, Kate A. Markey, MBBS, PhD, FRACP, MPH³ and Marie Bleakley, PhD, MBBS, MMSc⁴

¹Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
²Fred Hutchinson Cancer Research Center, Seattle, WA
³Fred Hutchinson Cancer Center, Seattle, WA
⁴Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA

4772

Mitochondrial Augmentation of Hematopoietic Stem and Progenitor Cells As a New Therapeutic Approach for Myelodysplasia

Takeshi Fujino¹^*, Noa Avni²^*, Neta Kutner²^*, Hanan Khoury²^*, Gat Pozner²^*, Niv Sabath²^*, Cynthia Castro³^*, Nina Fox³^*, Alexander M. Lewis⁴^*, Steven Tittley³^*, Oren Ziv²^*, Yishai Ofran, MD⁵, Tina Napso²^*, Natalie Yivgi Ohana, PhD²^*, Noa Sher, PhD²^* and Omar Abdel-Wahab, MD⁶

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Minovia Therapeutics, Tirat Carmel, Israel
³Memorial Sloan Kettering Cancer Center, New York
⁴Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Hematology and Stem Cell Transplantation Department, Sharee Zedek Medical Center, Jerusalem, Jerusalem, Israel
⁶Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

4773

Donor-Derived Unlicensed NK Cells Promote the Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation

Ding Yiyang, BS^*, Ming Zhao, MD^*, Xiang Wang, MD^*, Juan Xie, MD, PhD^*, Qian-Nan Shang, MD, PhD^*, Xun-Hong Cao, MD, PhD^*, Xiaohui Zhang, Xiao-Jun Huang, MD, PhD and Xiangyu Zhao, MD, PhD

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

4774

Enhancing Hematopoietic Stem and Progenitor Cell Mobilization with 27-Hydroxycholesterol and Cyp7b1 Inhibitors

Brandon Vu, BS¹^*, Travis Roeder, BA¹, Jitendra K. Kanaujiya, PhD¹^*, Amy Kimble¹^*, Eddy Tsang¹^*, Jeffrey McDonald, PhD²^* and Hideyuki Oguro, PhD³

¹University of Connecticut School of Medicine, Farmington, CT
²University of Texas Southwestern Medical Center, Dallas, TX
³University of Connecticut Health Center, Farmington, CT

4775

MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

Alexander Link, PhD¹^*, Teresa Maria Frasconi, PhD²^*, Stephan Wullschleger, PhD²^*, Natalia Venetz, PhD²^*, Alison Ribeiro, PhD²^*, Anja Schlegel, PhD²^*, Yvonne Kaufmann²^*, Alienor Auge²^*, Waleed Ali²^*, Norbert Fic²^*, Zoya Siddiqui²^*, Aline Eggenschwiler²^*, Sarah Jetzer²^*, Simon Häberle²^*, Dragana Prekajski²^*, Hilde De Winter, MD², Keith M. Dawson, PhD²^*, Amélie Croset, PhD²^* and Anne Goubier, PhD²^*

¹Molecular Partners AG, Schlieren-Zurich, Switzerland
²Molecular Partners AG, Zurich-Schlieren, Switzerland

4776

Donor T-Derived Memory Progenitors Differentiated into CD103^+/-CXCR6⁺CD4⁺ Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease

Xiaohui Kong, PhD^1,2^*, Bixin Wang, MD, PhD¹^*, Xiwei Wu, PhD, MD³^*, Weijia Fu¹^*, Qinjian Li¹^*, Moqian Zheng^1,2^*, Raju Pillai, MD⁴^*, Ryotaro Nakamura, MD⁵, Paul J. Martin, MD⁶ and Defu Zeng, MD^1,2

¹Department of Immunology and Theranostics, Arthur Riggs Institute of Diabetes and Metabolism Research, Beckman Research Institute of City of Hope, Duarte, CA
²Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Comprehensive Cancer Center, Duarte, CA
³Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA
⁴Department of Pathology, City of Hope National Comprehensive Cancer Center, Duarte, CA
⁵Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
⁶Fred Hutchinson Cancer Center, Seattle, WA

4777

EZH2 Inhibition Alleviates Chronic Graft-Versus-Host Disease By Modulating Lipid Metabolic Reprogramming and Senescence of Neutrophils

Qing Xu^1,2^*, Ya Zhou^1,2^*, Yuxi Xu, MS^2,3^*, Rui Wang^1,2^*, Xiaoqi Wang, MD^1,4^*, Shijie Yang, PhD^1,5^*, Qingxiao Song^2,6^* and Xi Zhang, PhD^2,7,8

¹Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China
²Jinfeng Laboratory, Chongqing, China
³Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, AL, China
⁴Army medical University affiliated Xinqiao Hospital, Chongqing, China
⁵Army Military Medical University, Chongqing, China
⁶Xinqiao Hospital of Army Medical University, Chongqing, China
⁷Affiliated xinqiao Hospital of Army medical University,chongqing ,China, chongqing city, China
⁸Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China

4778

Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

Ioulia Mavrikou¹^*, Daniela Taurino²^*, Tasoula Touloumenidou³^*, Zoi Bousiou, MD⁴^*, Evaggelia-Evdoxia Koravou¹^*, Anna Vardi, MD⁴^*, Apostolia Papalexandri, MD⁵^*, Christos Demosthenous, MD⁵^*, Maria Koutra¹^*, Alkistis Kyra Panteliadou, MD⁵^*, Ioannis Batsis¹^*, Evangelia Yannaki, MD^5,6^*, Dimitrios Chatzidimitriou⁷^*, Emmanouil Nikolousis, MD, MBBS, PhD, FRCP, FRCPath, MBA⁸^*, Alessandro Rambaldi²^*, Ioanna Sakellari, MD, PhD⁴^* and Eleni Gavriilaki, MD, PhD⁹

¹Hematology Department-BMT Unit, George Papanikolaou General Hospital, Thessaloniki, Greece
²Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy
³Hematology Department-BMT Unit, Georgios Papanikolaou General Hospital, Thessaloniki, Greece
⁴Hematology Department – BMT Unit, George Papanikolaou General Hospital, Thessaloniki, Greece
⁵Hematology Department – BMT Unit, G Papanicolaou Hospital, Thessaloniki, Greece
⁶Gene and Cell Therapy Center, Hematology Department-Hematopoietic Cell Transplantation Unit, George Papanikolaou General Hospital, Thessaloniki, Greece
⁷Microbiology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
⁸Department of Haematology, American Hospital Dubai UAE, Dubai, United Arab Emirates
⁹Aristotle University of Thessaloniki, Thessaloniki, Greece

4779

Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

George S. Laszlo, PhD¹^*, Brenda M. Sandmaier, MD^2,3, David J. King, PhD⁴^*, Allie R. Kehret²^*, Kyle E. Nyberg²^*, Jacob W. Barton²^*, Frances M. Cole²^*, Junyang Li²^*, Margaret C. Lunn-Halbert²^*, Donald K. Hamlin⁵^*, D. Scott Wilbur, PhD⁵^*, Johnnie J. Orozco, MD, PhD^2,6, Shannon L. Dexter²^* and Roland B. Walter, MD, PhD, MS^7,8,9

¹1100 Fairview Avenue North, Fred Hutchinson Cancer Center, Seattle, WA
²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
³Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA
⁴Lassen Therapeutics, San Diego, CA
⁵Department of Radiation Oncology, University of Washington, Seattle, WA
⁶Department of Medicine/Division of Hematology and Oncology, University of Washington, Seattle, WA
⁷Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA
⁸Fred Hutchinson Cancer Center, Seattle, WA
⁹Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA

4780

ER Stress Sensor PERK Boosts T Cell Pathogenicity in Gvhd through Regulating ERAD

Qiao Cheng, PhD¹^*, Heejin Choi, PhD¹^*, Yongxia Wu, MD, PhD¹, Linlu Tian, PhD¹^*, Michael Hendrix¹^* and Xue-Zhong Yu, MD, MSc²

¹Department of Microbiology & Immunology; the Cancer Center, Medical College of Wisconsin, Milwaukee, WI
²Department of Microbiology & Immunology; the Cancer Center, Medical College of Wisconsin, Milaukee, WI

4780.1

Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

Elizabeth Krakow, MD, MSc¹, Laura Connelly-Smith, DM, MBBChir¹^*, Catherine J. Lee, MD, MSc¹, Dow Dunbar, PA-C, MPH, MS¹^*, Jeremy Barton, MBBS, MRCP(UK)²^*, Beatrice P. McQueen, PhD, MBA²^*, Geoffrey R. Hill, MD³ and Jacob S. Appelbaum, MD, PhD^1,4

¹Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
²Simcha IL-18, Inc., New Haven, CT
³Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
⁴Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH